Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06406686
Other study ID # REB24-0132
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 3, 2024
Est. completion date June 3, 2025

Study information

Verified date May 2024
Source University of Calgary
Contact George D Veenhuyzen, MD
Phone (403) 944-3385
Email George.Veenhuyzen@albertahealthservices.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A randomized controlled trial will be conducted to evaluate the efficacy of Ablation Index-guided high power - short duration (HPSD) ablation compared to conventional power settings in Cavotricuspid Isthmus (CTI) dependent atrial flutter. Participants will be randomized to receive either AI-guided HPSD ablation at 50 Watts or conventional power settings at 30 Watts. Both arms will use the Carto 3D mapping system and the QDOT MICRO ablation catheter (Biosense Webster). An anatomically contiguous line will be created with <6mm inter-lesion distance. After a standardized wait time of 30 minutes, ablation success will be assessed. The primary outcome is total radiofrequency ablation time. Secondary outcomes include procedural time, fluoroscopy time, safety outcomes, and 3-month freedom from recurrence. It is our expectation that HPSD will result in a shorter primary outcome.


Description:

Title: A Randomized Trial of Ablation Index Guided High vs Standard Power Radiofrequency Ablation for Typical Atrial Flutter Design: Prospective, two-arm, single center, superiority study with comparison of standard 30W power settings vs 50W high power settings Purpose: To evaluate the superiority of high-power ablation settings over standard power settings in achieving block across the CTI for typical flutter Enrollment: A minimum of 25 subjects in each arm. Enrollment over a period of 12 months. Subjects: Subjects referred by a cardiac electrophysiologist for standalone radiofrequency ablation of typical atrial flutter Clinical site: Foothills Medical Center, University of Calgary, Calgary, Alberta, Canada Endpoints: Primary endpoint: total radiofrequency time per procedure Secondary endpoints: RF time to initial CTI block Total procedure time Time from procedure start to procedure end Incidence of early reconnections during wait period Incidence of dormant conduction during adenosine testing Total number of ablation lesions required to achieve durable CTI block Total analgesia and sedation usage, e.g. midazolam, fentanyl and propofol in mg and/or mL Post-procedure patient perception of a) pain and b) nausea on a scale of 1 (none) to 10 (maximum possible) Secondary safety endpoints: Steam pops Pericardial effusions Pericardial tamponade Secondary follow-up outcomes: The presence of durable CTI block if a subsequent EP study is performed within 3 months of the initial procedure (e.g. AF ablation) Recurrence of documented AFL within 3 months by available ECGs, telemetry, wearable monitors, or Holters Holter at 2 months for incidence and burden of atrial arrhythmias Materials: 3-D electro-anatomical mapping system: CARTO, Biosense Webster Diagnostic catheters: 20-pole halo catheter, 10 pole coronary sinus catheter Ablation catheter: QDOT MICRO, BiosenseWebster Sponsors: None, fellow initiated research Despite the existing observational data, there have been no randomized controlled trials (RCTs) investigating HPSD in CTI ablation to validate its effectiveness. Furthermore, the applicability of AI to CTI ablation has not been tested. It's important to note that CTI ablation, performed under conscious sedation, introduces respiratory movement, leading to increased CF variability, which may affect precise energy delivery. We propose conducting the first RCT, to our knowledge, investigating the use of High-Power Short-Duration Ablation (HPSD) in the treatment of CTI-dependent flutter.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date June 3, 2025
Est. primary completion date June 3, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Clinically determined by a cardiac electrophysiologist to have had at least one episode of CTI dependent atrial flutter 2. Clinically determined by a cardiac electrophysiologist likely to benefit from standalone CTI ablation 3. For this to be their first CTI ablation attempt 4. Able and willing to comply with all protocol requirements 5. Agree to and sign patient Informed Consent Form (ICF) 6. Be 18 years of age or older Exclusion Criteria: 1. Previous CTI ablation 2. Adult congenital heart disease, including Ebstein's anomaly 3. Previous surgery involving the tricuspid valve and atrium including cannulation scars for cardiopulmonary bypass 4. Pediatric population age <18 5. Women who are pregnant or breastfeeding. 6. Active enrollment in another investigational study involving a drug or device. 7. A requirement for additional procedures in the same setting. Such as EP study and ablation of other induced arrhythmias since these prolong secondary endpoints such as procedure time and RF time 8. Patients on anti-arrhythmic drugs (AADs) such as flecainide, sotalol, or amiodarone should have their AAD stopped 3 days prior, and not be restarted after the procedure 9. Patients under General Anesthetic (GA) 10. Patients with sufficient baseline cognitive impairment to be unable to answer a post-procedure survey or consent Previous ablations, other than for CTI flutter, are acceptable.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Ablation of the Cavo-tricuspid isthmus for typical Atrial Flutter
Durable block across the cavotricuspid isthmus by radiofrequency ablation.

Locations

Country Name City State
Canada University of Calgary Calgary Alberta

Sponsors (1)

Lead Sponsor Collaborator
University of Calgary

Country where clinical trial is conducted

Canada, 

References & Publications (1)

Golian M, Ramirez FD, Alqarawi W, Hansom SP, Nery PB, Redpath CJ, Nair GM, Shaw GC, Davis DR, Birnie DH, Sadek MM. High-power short-duration radiofrequency ablation of typical atrial flutter. Heart Rhythm O2. 2020 Oct 3;1(5):317-323. doi: 10.1016/j.hroo.2020.09.002. eCollection 2020 Dec. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary RF time to durable CTI block Cumulative delivery time of radio-frequency lesions End of procedure
Secondary RF time to initial CTI block At the point of initial CTI block, the total cumulative time applying radiofrequency energy End of procedure
Secondary Total procedure time Time from procedure start to procedure end End of procedure
Secondary Incidence of early re-connections during wait period Whether or not conduction was observed across the CTI before the wait period had expired End of procedure
Secondary Total number of ablation lesions required to achieve durable CTI block At the point of durable CTI block, the total cumulative number of radiofrequency lesions deployed End of procedure
Secondary Total analgesia and sedation usage Cumulative doses of sedation and analgesic medicines End of procedure
Secondary Post-procedure patient perception of pain and nausea Post-procedure patient perception of a) pain and b) nausea on a scale of 1 (none) to 10 (maximum possible) assessed after the procedure and prior to discharge. End of procedure day
Secondary Steam pops Count of audible "steam-pops" during the procedure End of procedure
Secondary Pericardial effusions Observation of new effusion after the procedure End of procedure day
Secondary Pericardial tamponade Observation of hemodynamically significant pericardial effusion periprocedurally warranting intervention End of procedure day
See also
  Status Clinical Trial Phase
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Terminated NCT02317029 - Comparison of Oxygen Interventions and Defibrillator Efficiency N/A
Recruiting NCT01563848 - Cryoablation in Patients With Atrial Flutter Phase 2
Completed NCT01229254 - Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter Phase 2
Completed NCT00839657 - Clarification of Optimal Anticoagulation Through Genetics Phase 3
Completed NCT02065388 - Pharmacogenetic Dosing of Warfarin Phase 3
Completed NCT00232232 - Use of Fish Oils to Prevent Atrial Mechanical Stunning and Atrial Remodeling Due to Atrial Arrhythmia Phase 4
Completed NCT04884100 - enHEART - Exploring Full Content of Optical Signals to Enhance Cardiac Arrhythmia Screening N/A
Completed NCT05468281 - RAFF5 Proposal: Improve the Quality and Safety of Patients Seen in the Emergency Department for Acute Atrial Fibrillation and Flutter
Completed NCT03627143 - Decreasing Hospital Admissions From the ED for AAFF N/A
Completed NCT02917538 - A Randomized Trial of Contact Force in Atrial Flutter Ablation N/A
Enrolling by invitation NCT05903313 - A Study to Evaluate Accuracy and Validity of the Chang Gung ECG Abnormality Detection Software
Recruiting NCT05755074 - Ablation of Typical Right Atrial Flutter N/A
Recruiting NCT05883631 - RESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy. N/A
Recruiting NCT03272620 - Atrial Fibrillation at the Viennese University Emergency Department N/A
Completed NCT02810938 - MIFI Flutter Registry - Ablation of Atrial Flutter With IntellaTip Sensor Technology
Recruiting NCT02591875 - Atrial Flutter Ablation in a Real World Population N/A
Completed NCT01914497 - Dipole Density Mapping of Typical Atrial Flutter N/A
Completed NCT02268799 - High Sensitivity Troponin T Levels Following DC Cardioversion for Atrial Fibrillation / Atrial Flutter N/A
Active, not recruiting NCT01976507 - Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism Phase 4